Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by ANALIAS00on Mar 02, 2018 1:54pm
127 Views
Post# 27652825

RE:RE:33 days until april 3

RE:RE:33 days until april 3We are in a situation where we (few investors on this board) believe we are right and that the world (thousands of investors (market)) are wrong.

We all see a lot of evidences that Trogarzo and TH should succeed.  Maybe we have to much expectations.  But if it turns out that this drug is largely prescribed to MDR HIV patients in US, and the stock quickly reach $20 because investors finally see potential with Canada and Europe market comming, and because TH do gets other product to distribute, etc, well we will all be questionning why this stock was as low as $6.90 few days from the approval with so many obvious evidences.    TH may become an interesting case to study and understand why investors refused to see of believe the facts.  Question of confidence I guess.

If it turns out to be a "ptard mouill", well, it would not be the first one  :) 
Bullboard Posts